Lantheus Q1 2026 slides: regulatory wins fuel growth transition

Lantheus beat Q1 2026 expectations with adjusted EPS of $1.46 versus $1.23 consensus and revenue of $377.3 million versus $354.9 million, while reaffirming full-year guidance of $1.4 billion-$1.45 billion in revenue and $5.00-$5.25 in adjusted EPS. Growth was supported by NeuraCeq (+14.3% sequentially) and DEFINITY (+6.8% YoY), offset by a 6.5% decline in PYLARIFY sales amid pricing pressure. The stock rose in premarket trading as the company also highlighted FDA approvals and launch progress for PYLARIFY TruVu, OCTEVY, and PNT2003.

Analysis

The market is rewarding a transition story, but the real signal is that LNTH is shifting from a single-franchise growth trade to a portfolio with more durable cash conversion. That matters because the company now has multiple internal offsets: softer pricing in the legacy imaging franchise can be partially absorbed by new-account penetration in amyloid imaging and by the operating leverage embedded in the manufacturing upgrade path. In other words, this is less about the quarter and more about the probability that 2027 becomes a cleaner comp year with higher mix and better supply economics.

The biggest second-order effect is competitive: the TruVu rollout should raise the barrier to entry by making supply reliability and manufacturing integration part of the product pitch, not just clinical differentiation. That tends to punish smaller radiopharma players that can match efficacy claims but not distribution resilience. It also creates a window where hospital systems and large imaging centers may rationalize vendor concentration, which could help the incumbent defend share even if list-price growth remains muted.

The contrarian risk is that the stock is being priced on multiple future catalysts that are not all independent. If the OCTEVY timeline slips again or PNT2003 is delayed by litigation, investors may start discounting the entire 2027 acceleration thesis and re-rate LNTH as a mature cash cow rather than a growth compounder. The other risk is that management’s confidence in buybacks and guidance may mask a plateauing core franchise; if PSMA volumes decelerate after the current transition, the market could compress the multiple quickly despite the optically strong FCF.

Net: this is attractive on 3-12 month setup, but not because the quarter was clean—it’s because the next 2-3 catalysts create asymmetry if execution holds. The move looks partly justified, but not fully flushed until investors see whether the manufacturing transition can preserve volumes while improving economics.

Key Decisions for Investors

• Maintain/add to LNTH long only on intraday pullbacks or post-gap consolidation; target 6-9 month upside tied to TruVu/OCTEVY/PNT2003 optionality, but keep a tight stop if the stock loses the post-earnings breakout zone.
• Buy LNTH call spreads for a 3-6 month horizon to express upside while capping event risk from regulatory slippage; best use if implied vol remains elevated after the move.
• Pair trade: long LNTH vs short a higher-multiple radiopharma/diagnostics peer with weaker cash generation and less manufacturing control; the trade benefits if investors start rewarding supply-chain resilience over pure pipeline beta.
• If LNTH rallies another 10-15% before a second catalyst, take partial profits and roll into a lower-delta structure; the stock is likely to trade headline-to-headline through the summer.
• Avoid chasing outright common stock here if OCTEVY/PNT2003 timing is central to the thesis; the best risk/reward is entry on weakness, not after a two-day re-rating.